Minerva Neurosciences, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Minerva Neurosciences files an amendment to its annual report to include missing Inline eXtensible Business Reporting Language (XBRL) data tagging.
NASDAQ
10-K/A: Minerva Neurosciences Files Amendment to 10-K Report, Updates Executive and Director Information
Minerva Neurosciences files an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, corporate governance, and executive compensation.
NASDAQ
10-K: Minerva Neurosciences Faces FDA Roadblock for Roluperidone, Outlines Path Forward in Annual Report
Minerva Neurosciences reports a net income of $1.4 million for 2024 but faces challenges as the FDA issues a Complete Response Letter for its roluperidone NDA, requiring additional studies.
NASDAQ
10-K/A: Minerva Neurosciences Files Amended 10-K Report, Details Executive Compensation and Governance
Minerva Neurosciences has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.
NASDAQ
Minerva Neurosciences has filed an amendment to its annual report to correct a typographical error in the date of the independent auditor's consent.
NASDAQ
Minerva Neurosciences has filed its annual 10-K report, detailing its financial status and providing updates on its key drug development programs, particularly roluperidone.